The following is a summary of “Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial,” published in the November 2023 issue of Dermatology by Bagel, et al.

Tapinarof cream 1%, when applied once daily, has shown significant efficacy and safety in two 12-week, phase 3 pivotal trials involving adults with mild-to-severe plaque psoriasis. For a study, researchers sought to evaluate the long-term effects of tapinarof on health-related quality of life and patient satisfaction.

Patients who completed the initial 12-week trials were eligible to continue treatment with open-label tapinarof based on their Physician Global Assessment scores as part of the PSOARING 3 study. Patients’ Dermatology Life Quality Index (DLQI) was assessed at each visit, and a Patient Satisfaction Questionnaire was administered at week 40 or upon early termination.

A total of 763 patients (91.6% of eligible patients) enrolled in the long-term extension study, with 78.5% of them completing the Patient Satisfaction Questionnaire. DLQI scores showed sustained improvement throughout the study, indicating enhanced quality of life. By week 40, 68.0% of patients achieved a DLQI score of 0 or 1, indicating that psoriasis had no impact on their health-related quality of life. The Patient Satisfaction Questionnaire results revealed that most patients strongly agreed or agreed with all questions related to their confidence in tapinarof, satisfaction with its efficacy (62.9%-85.8%), ease of application and cosmetic elegance (79.9%-96.3%), and preference for tapinarof over previous psoriasis treatments (55.3%-81.7%).

The research demonstrated that tapinarof cream leads to ongoing and lasting improvements in health-related quality of life, and patients reported high levels of satisfaction, endorsing their positive views of tapinarof’s effectiveness and ease of use.

Source: jaad.org/article/S0190-9622(23)00771-5/fulltext